Invitrogen opens Australian cGMP manufacturing facility

Thursday, 25 August, 2005

Invitrogen has opened a AU$3.4 million cGMP bioproduction facility focused on the development of safe and consistent bovine sera products and reagents used in basic research and the production of vaccines and biotherapeutic drugs for world markets.

cGMP refers to good manufacturing practices required in the design and operation of the facility, processes and quality systems in order to serve global pharmaceutical companies. Invitrogen's site also features new process technology and automation optimised for the standards expected by biopharmaceutical customers.

Australia and New Zealand are among the few countries regarded as being BSE free, as well as having a lower incidence of other viral diseases prevalent in other countries. As a result, global pharmaceutical companies are seeking secure supply of locally produced biotechnology products.

This reputation is important as it encourages global biopharmaceutical customers to source product from this part of the world. It is a global advantage that may encourage Invitrogen to continue to review opportunities to expand its operations in Australia.

Related News

Vibrating worm wins Aus researchers 2020 Ig Nobel Prize

The researchers won the Ig Nobel Physics Prize for determining what happens to the shape of a...

Strategic alliance: Millennium Science and Jomar Life Research

The companies will form a strategic alliance under common ownership to provide A/NZ researchers...

Logistics requirements for a COVID-19 vaccine

DHL has published a white paper on delivering stable logistics for vaccines and medical goods...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd